<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01456572</url>
  </required_header>
  <id_info>
    <org_study_id>EKBB 122/09</org_study_id>
    <nct_id>NCT01456572</nct_id>
  </id_info>
  <brief_title>Gastric and Intestinal Satiation in Obese and Normal Weight Healthy People</brief_title>
  <official_title>Gastric and Intestinal Satiation in Obese and Normal Weight Healthy People</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the reciprocal control between gastric functions
      and intestinal parameters in the development of satiation in obese people.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity has reached pandemic proportions, obesity-associated complications are extensive and
      the current treatment options are limited. These facts demonstrate the need for an improved
      understanding of the pathogenesis of obesity. The gastrointestinal tract plays a key element
      in the control of satiation; discrepancies exist, however, for the role of gastric and
      intestinal parameters in the control of satiation in relation to body mass. To achieve a
      comprehensive understanding for the reciprocal control between gastric functions and
      intestinal parameters in the development of satiation in obese people the investigators will
      compare satiation parameters, gastric emptying and plasma glucagon-like peptide-1 (GLP-1),
      peptide tyrosine tyrosine (PYY) and ghrelin levels between normal and obese healthy
      volunteers.

      Time needed to reach the level of satiation and total calorie intake will be measured by a
      standardized nutrient drink test; gastric emptying of solids by a 13C-octanoic acid breath
      test; and plasma GLP-1, PYY and ghrelin levels will be measured after a standardized nutrient
      drink.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>gastrointestinal peptide secretion</measure>
    <time_frame>2 hours blood sampling</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>gastric emptying</measure>
    <time_frame>240 minutes end-expiratory breath sample collection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time needed to reach the level of satiation</measure>
    <time_frame>up to 30 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total calorie intake</measure>
    <time_frame>up to 30 min</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Endocrine System Diseases</condition>
  <arm_group>
    <arm_group_label>satiation_obese weight</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obese subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gastric emptying_obese weight</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obese subjects will receive a standardized meal, consisting of two scrambled eggs (cooked with 10 g butter), placed on two slices of whole wheat bread and 200 mL of milk (in total: 468 kcal). The test meal will be labeled with 100 mg of 13C-octanoic acid for determination of gastric emptying.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gastric emptying_normal weight</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal weight subjects will receive a standardized meal, consisting of two scrambled eggs (cooked with 10 g butter), placed on two slices of whole wheat bread and 200 mL of milk (in total: 468 kcal). The test meal will be labeled with 100 mg of 13C-octanoic acid for determination of gastric emptying.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>satiation_normal weight</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal weight subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hormone profiles_obese weight</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obese subjects will receive 500 mL of a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate). At regular time intervals fasting and post-prandial blood samples will be collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hormone profiles_normal weight</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal weight subjects will receive 500 mL of a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate). At regular time intervals fasting and post-prandial blood samples will be collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ensure plus</intervention_name>
    <description>17 % protein, 30 % fat and 53 % carbohydrate; 1 kcal/mL</description>
    <arm_group_label>satiation_obese weight</arm_group_label>
    <arm_group_label>satiation_normal weight</arm_group_label>
    <arm_group_label>hormone profiles_obese weight</arm_group_label>
    <arm_group_label>hormone profiles_normal weight</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>standardized test meal</intervention_name>
    <description>scrambled eggs, two slices of whole wheat bread, 200 mL of milk and labeled with 13C-octanoic acid</description>
    <arm_group_label>gastric emptying_obese weight</arm_group_label>
    <arm_group_label>gastric emptying_normal weight</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy subjects

          -  age 18-45

        Exclusion Criteria:

          -  smoking

          -  substance abuse

          -  regular intake of medication

          -  medical or psychiatric illness

          -  gastrointestinal disorders or food allergies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Beglinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phase 1 Research Unit, University Hospital Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel, Phase 1 Research Unit</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2011</study_first_submitted>
  <study_first_submitted_qc>October 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>October 18, 2011</last_update_submitted>
  <last_update_submitted_qc>October 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glucagon-like peptide-1</keyword>
  <keyword>peptide tyrosine tyrosine</keyword>
  <keyword>ghrelin</keyword>
  <keyword>stomach</keyword>
  <keyword>small intestine</keyword>
  <keyword>gastric emptying</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

